UltraPlasma™ Multi-Platform Plasma Systems for Discoid Lupus Erythematosus (DLE) Treatment

Introduction

Discoid Lupus Erythematosus (DLE) is a chronic autoimmune skin condition characterized by inflamed, disc-shaped lesions, often resulting in scarring and pigmentation loss. Traditional therapies focus on immunosuppression and inflammation control. However, UltraPlasma™—a next-generation plasma therapy system integrating arc, argon, and helium plasmas—offers a novel non-invasive approach. This system utilizes a custom software-hardware spectrum controller to deliver precise reactive species, improve microcirculation, and support immune modulation directly at the skin interface.

1. Pathophysiology of Discoid Lesions (DLE)

DLE lesions typically involve:

• Epidermis: Hyperkeratosis, basal cell degeneration, and interface dermatitis.

• Dermis: Perivascular inflammation and lymphocytic infiltration.

• Hypodermis: Involvement in deep scarring and tissue breakdown in chronic cases.

• Blood functions: Reduced perfusion, oxygenation, and immune dysfunction.

• Immune dysfunction: T-cell hyperactivation, autoantibody production (e.g., anti-Ro/SSA), and impaired resolution of inflammation.

2. UltraPlasma™ System Overview

The UltraPlasma™ device integrates three plasma sources and modulates them via a real-time spectrum controller:

3. Plasma-Induced Mechanisms in DLE Treatment

3.1 Epidermal Repair and Resurfacing

• UltraPlasma™ arc plasma mode delivers UV-like excitation to reduce hyperkeratosis.

• Ozone (O₃) and NO enhance local antioxidant defenses and DNA repair enzymes.

• UltraPlasma™ argon plasma mode balances keratinocyte regeneration without thermal damage.

3.2 Dermal Microcirculation and Fibroblast Activation

• UltraPlasma™ helium plasma mode modulates deep fibroblasts and endothelial cells.

• Controlled NO release promotes vasodilation, tissue oxygenation, and healing.

3.3 Hypodermal Immunomodulation

• Deep penetration of helium plasma aids lymphatic drainage and immune regulation.

• RNS (Reactive Nitrogen Species) balance T-reg vs. Th17 cell ratios.

4. Role of Reactive Gases and Blood Interaction

⌘Conclusion⌘

UltraPlasma™ represents a paradigm shift in the treatment of Discoid Lupus Erythematosus (DLE), offering a multi-layered therapeutic approach that extends beyond surface-level symptom management. By integrating arc, argon, and helium plasma technologies into a harmonized output system, UltraPlasma™ delivers a precise spectrum of energy and reactive gas species tailored to the biological demands of each skin layer—epidermis, dermis, and hypodermis.

Through the synergistic effects of ozone (O₃), nitric oxide (NO), and other plasma-induced reactive species, the device not only reduces inflammatory lesions but also revitalizes microcirculation, repairs dermal architecture, and actively modulates dysfunctional immune responses. This positions UltraPlasma™ as both a regenerative and immune-regulatory therapy—an ideal match for the multifactorial nature of autoimmune skin conditions like DLE.

With customizable treatment protocols and non-invasive application, UltraPlasma™ provides dermatologists with a safe, versatile, and highly effective tool to manage chronic discoid lesions, reduce relapse rates, and enhance patients’ skin integrity and quality of life. As plasma medicine continues to evolve, UltraPlasma™ sets a new benchmark in combining advanced bioelectrical engineering with immuno-dermatological care.

5. Immune System Repair Strategy via UltraPlasma™

• Targeted plasma pulses reduce autoreactive T-cell clusters.

• NO and O₃ upregulate anti-inflammatory cytokines (IL-10, TGF-β).

• Arc plasma’s ROS bursts help reset local immune cell metabolism.

• Longitudinal treatments shift from inflammation to regeneration phase.

6. Suggested Treatment Protocol

Shortcut for our Goals!

▼